For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Efficacy and Tolerability of Pegylated Interferon-α2a plus Ribavirin versus Pegylated Interferon-α2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C PatientsLee S.a · Kim I.H.a · Kim S.H.a · Kim S.W.a · Lee S.O.a · Lee S.T.a · Kim D.G.a · Lee C.S.a · Choi C.S.b · Cho E.Y.b · Kim H.C.b
aDepartment of Internal Medicine, Research Institute for Medical Science, Chonbuk National University Medical School and Hospital, Jeonju, and bDepartment of Internal Medicine, Wonkwang University College of Medicine and Hospital, Iksan, South Korea Corresponding Author
In Hee Kim, MD
Department of Internal Medicine, Research Institute of Clinical Medicine
Chonbuk National University Medical School and Hospital
634-18 Keumam-dong, Dukjin-ku, Jeonju, Jeonbuk 561-712 (South Korea)
Tel. +82 63 250 1677, Fax +82 63 254 1609, E-Mail firstname.lastname@example.org
Objectives: The authors compared the efficacies and tolerabilities of pegylated interferon-α2a (PEG-IFN-α2a) + ribavirin and pegylated interferon-α2b (PEG-IFN-α2b) + ribavirin for the initial treatment of chronic hepatitis C. Methods: A total of 126 treatment-naive patients (29.4% genotype 1, 70.6% genotype non-1) were treated with PEG-IFN-α2a 180 µg/week (group A, n = 79) or PEG-IFN-α2b 1.5 µg/kg/week (group B, n = 47) with ribavirin (800 mg/day for genotype non-1 or 1,000–1,200 mg/day for genotype 1) for 24 (genotype non-1) or 48 weeks (genotype 1). Results: End-of-treatment virologic response, sustained virologic response, and biochemical response were not significantly different in groups A and B (84.8 vs. 89.4%, 70.9 vs. 72.3%, and 70.9 vs. 74.5%, respectively; p > 0.05). In patients with the HCV genotype 1 or non-1, treatment responses were not significantly different. Multivariate analysis showed that HCV genotype only was an independent factor that affected sustained virologic response (p = 0.048). The proportions of treatment discontinuations in groups A and B were similar (10.1 vs. 10.6%; p = 1.000). Conclusions: PEG-IFN-α2a or PEG-IFN-α2b + ribavirin combination therapies showed similar efficacies and tolerabilities as initial treatments for chronic hepatitis C.
© 2010 S. Karger AG, Basel